{
    "root": "a0837632-a29a-4588-8979-73aa52d27193",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "JUNEL FE 28 DAY",
    "value": "20250501",
    "ingredients": [],
    "indications": "Junel 21 and Junel Fe 28 are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.\n                  Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.\n                  \n                     TABLE I: LOWEST EXPECTED AND TYPICAL FAILURE RATES DURING THE FIRST YEAR OF CONTINUOUS USE OF A METHOD\n                     \n                     \n                     \n                     \n                        \n                           \n                              % Of Women Experiencing an Unintended Pregnancy in the First Year of Continuous Use\n                           \n                        \n                        \n                           \n                              Method\n                           \n                           \n                              Lowest\n            Expected*\n                              \n                           \n                           \n                              Typical**\n                              \n                           \n                        \n                        \n                           \n                              (No contraception)\n                           \n                           \n                              (85)\n                           \n                           \n                              (85)\n                           \n                        \n                        \n                           \n                              Oral contraceptives\n            combined\n            progestin only\n                           \n                           \n                               0.1\n            0.5\n                           \n                           \n                              3\n            N/A***\n                                 \n            N/A***\n                              \n                           \n                        \n                        \n                           \n                              Diaphragm with spermicidal cream or jelly\n                           \n                           \n                              6\n                           \n                           \n                              20\n                           \n                        \n                        \n                           \n                              Spermicides alone (foam, creams, gels, vaginal suppositories, and vaginal film)\n                           \n                           \n                              6\n                           \n                           \n                              26\n                           \n                        \n                        \n                           \n                              Vaginal Sponge\n            nulliparous\n            parous\n                           \n                           \n                               9\n            20\n                           \n                           \n                               20\n            40\n                           \n                        \n                        \n                           \n                              Implant\n                           \n                           \n                              0.05\n                           \n                           \n                              0.05\n                           \n                        \n                        \n                           \n                              Injection: depot medroxyprogesterone acetate\n                           \n                           \n                              0.3\n                           \n                           \n                              0.3\n                           \n                        \n                        \n                           \n                              IUD\n            progesterone T\n            copper T 380A\n            LNg 20\n                           \n                           \n                               1.5\n            0.6\n            0.1\n                           \n                           \n                               2\n            0.8\n            0.1\n                           \n                        \n                        \n                           \n                              Condom without spermicides\n            female\n            male \n                           \n                           \n                               5\n            3\n                           \n                           \n                               21\n            14\n                           \n                        \n                        \n                           \n                              Cervical Cap with spermicidal cream or jelly\n            nulliparous\n            parous\n                           \n                           \n                              9\n            26\n                           \n                           \n                              20\n            40\n                           \n                        \n                        \n                           \n                              Periodic abstinence (all methods)\n                           \n                           \n                              1 to 9\n                           \n                           \n                              25\n                           \n                        \n                        \n                           \n                              Withdrawal\n                           \n                           \n                              4\n                           \n                           \n                              19\n                           \n                        \n                        \n                           \n                              Female sterilization\n                           \n                           \n                              0.5\n                           \n                           \n                              0.5\n                           \n                        \n                        \n                           \n                              Male sterilization\n                           \n                           \n                              0.10\n                           \n                           \n                              0.15\n                           \n                        \n                        \n                           \n                              Adapted from RA Hatcher et al, Reference 7.\n                           \n                        \n                        \n                           \n                              * The authors' best guess of the percentage of women expected to experience an accidental pregnancy among couples who initiate a method (not necessarily for the first time)     and who use it consistently and correctly during the first year if they do not stop for any other reason.\n            \n                                 ** This term represents “typical” couples who initiate use of a method (not necessarily for the first time), who experience an accidental pregnancy during the first year if they do      not stop use for any other reason.\n                              \n                                 *** N/A-Data not available.",
    "contraindications": "The tablet dispenser has been designed to make oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in either three or four rows of seven tablets each, with the days of the week appearing on the tablet dispenser above the first row of tablets.\n                  \n                     Note: Each tablet dispenser has been preprinted with the days of the week, starting with Sunday, to facilitate a Sunday-Start regimen. Six different day label strips have been provided with the Detailed Patient & Brief Summary Patient Package Insert in order to accommodate a Day-1 Start regimen. If the patient is using the Day-1 Start regimen, she should place the self-adhesive day label strip that corresponds to her starting day over the preprinted days.\n                  \n                     Important: The patient should be instructed to use an additional method of protection until after the first week of administration in the initial cycle when utilizing the Sunday-Start regimen.\n                  The possibility of ovulation and conception prior to initiation of use should be considered.",
    "warningsAndPrecautions": "Junel®\n                      1/20 (21 Tablets) (norethindrone acetate 1 mg and ethinyl estradiol 20 mcg tablets, USP) are packaged in cartons of three blister cards. Each card contains 21 light yellow, round, flat-faced, beveled-edge, unscored tablets debossed with stylized b on one side and 977 on the other side. (NDC 0555-9025-42).\n                  \n                     Junel® \n                     \n                     Fe 1/20 (28 Tablets) (norethindrone acetate 1 mg and ethinyl estradiol 20 mcg tablets, USP, and ferrous fumarate tablets) are packaged in cartons of six blister cards. Each card contains 21 light yellow, round, flat-faced, beveled-edge, unscored tablets debossed with stylized b on one side and 977 on the other side and 7 brown, round, flat-faced, beveled-edge, unscored tablets debossed with stylized b on one side and 247 on the other side. Each brown tablet contains 75 mg ferrous fumarate. The ferrous fumarate tablets are present to facilitate ease of drug administration via a 28-day regimen, are non-hormonal, and do not serve any therapeutic purpose. (NDC 0555-9026-58).\n                  \n                     Junel®\n                      1.5/30 (21 Tablets) (norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg tablets, USP) are packaged in cartons of three blister cards. Each card contains 21 pink, round, flat-faced, beveled-edge, unscored tablets debossed with stylized b on one side and 978 on the other side. (NDC 0555-9027-42).\n                  \n                     Junel® Fe 1.5/30 (28 Tablets) (norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg tablets, USP, and ferrous fumarate tablets) are packaged in cartons of six blister cards. Each card contains 21 pink, round, flat-faced, beveled-edge, unscored tablets debossed with stylized b on one side and 978 on the other side and 7 brown, round, flat-faced, beveled-edge, unscored tablets debossed with stylized b on one side and 247 on the other side. Each brown tablet contains 75 mg ferrous fumarate. The ferrous fumarate tablets are present to facilitate ease of drug administration via a 28-day regimen, are non-hormonal, and do not serve any therapeutic purpose. (NDC 0555-9028-58).\n                  \n                     Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].",
    "adverseReactions": "Oral contraceptives are contraindicated in women who currently have the following conditions:\n                  \n                     Thrombophlebitis or thromboembolic disorders\n                     A past history of deep vein thrombophlebitis or thromboembolic disorders\n                     Cerebral vascular or coronary artery disease\n                     Current diagnosis of, or history of, breast cancer, which may be hormone sensitive\n                     Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia \n                     Undiagnosed abnormal genital bleeding\n                     Cholestatic jaundice of pregnancy or jaundice with prior pill use\n                     Hepatic adenomas or carcinomas\n                     Are receiving Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations (see Warnings, \n                           RISK OF LIVER ENZYME ELEVATIONS WITH CONCOMITANT HEPATITIS C TREATMENT\n                        )."
}